Developing effective delivery systems for Chlamydia vaccines

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 182-194

  Igietseme, Joseph U ^a,b   Eko, Francis O ^b   He, Qing ^a,b   Bandea, Claudiu ^a   Black, Carolyn M ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvants; Chlamydia; Delivery systems; Immunity; Immunomodulation; Vaccine; Vectors

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE;

ADULT; ARTICLE; CHLAMYDIA; CHLAMYDIASIS; ECONOMICS; FEMALE; HUMAN; IMMUNOLOGY; MUCOSAL IMMUNITY; PHYSIOLOGY; PREGNANCY;

ADULT; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA; CHLAMYDIA INFECTIONS; FEMALE; HUMANS; IMMUNITY, MUCOSAL; PREGNANCY;

EID: 2942754432     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Bush RM, Everett KD: Molecular evolution of Chlamydiaceae. Int J Syst Evol Microbiol (2001) 51(1):203-220.
2. Everett KD, Bush RM, Andersen AA: Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. Int J Syst Bacteriol (1999) 49(2):415-440.
3. Schachter J, Stephens RS, Timms P, Kuo C, Bavoil PM, Birkelund S, Boman J, Caldwell H, Campbell LA, Chernesky M, Christiansen G et al: Radical changes to chlamydial taxonomy are not necessary just yet. Int J Syst Evol Microbiol (2001) 51(1):251-253.
4. Stephens RS, Tam MR, Kuo C-C, Nowinski RC: Monoclonal antibodies to Chlamydia trachomatis: Antibody specificities and antigen characterization. J Immunol (1982) 128(3):1083-1089.
5. Stephens RS, Wagar EA, Schoolnik GK: High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J Exp Med (1988) 167(3):817-831.
6. Bandea CI, Kubota K, Brown TM, Kilmarx PH, Bhullar V, Yanpaisarn S, Chaisilwattana P, Siriwasin W, Black CM: Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein (OMP1). Sex Transm Infect (2001) 77(6):419-422.
7. Dean D, Schachter J, Dawson CR, Stephens RS: Comparison of the major outer membrane protein variant sequence regions of B/Ba isolates: A molecular epidemiologic approach to Chlamydia trachomatis infections. J Infect Dis (1992) 166(2):383-392.
8. Hayes LJ, Pecharatana S, Bailey RL, Hampton TJ, Pickett MA, Mabey DC, Watt PJ, Ward ME: Extent and kinetics of genetic change in the Omp1 gene of Chlamydia trachomatis in two villages with endemic trachoma. J Infect Dis (1995) 172(1):268-272.
9. Miyashita N, Fukano H, Hara H, Yoshida K, Niki Y, Matsushima T: Recurrent pneumonia due to persistent Chlamydia pneumoniae infection. Intern Med (2002) 41(1):30-33.
10. Schachter J: Infection and disease epidemiology. In: Chlamydia: Intracellular Biology, Pathogenesis, and Immunity. Stephens RS (Ed), ASM Press, Washington, DC, USA (1999):139-169.
11. WHO, global prevalence and incidence of selected curable sexually transmitted diseases: Overview and estimates. World Health Organisation, Geneva, Switzerland (1996).
12. Schachter J, Grayston JT: Epidemiology of human chlamydial infections. In: Chlamydial Infections. Stephens RS, Byrne GI, Christiansen G, Clarke IN, Grayston JT, Rank RG, Ridgway GL, Saikku P, Schachter J, Stamm WE (Eds), Berkeley, San Francisco, CA, USA (1998):3-10.
13. Johnson RE, Newhall WJ, Papp JR, Knapps JS, Black CM, Gift TL, Steece R, Markowitz LE, Devine OJ, Walsh CM, Wang S et al: Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections -2002. MMWR Morb Mortal Wkly Rep (2002) 51(RR15):1-27.
14. Groseclose SL, Zaidi AA, DeLisle SJ, Levine WC, St Louis ME: Estimated incidence and prevalence of genital Chlamydia trachomatis infections in the United States, 1996. Sex Transm Dis (1999) 26(6):339-344.
15. Paavonen J, Wolner-Hanssen P: Chlamydia trachomatis: A major threat to reproduction. Hum Reprod (1989) 4(2):111-124.
16. Stamm WE, Guinan ME, Johnson C, Starcher T, Holmes KK, McCormack WM: Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med (1984) 310(9):545-549.
17. Rees E: Treatment of pelvic inflammatory disease. Am J Obstet Gynecol (1980) 138(7 Pt 2):1042-1047.
18. Westrom L, Joesoef R, Reynolds G, Hadgu A, Thompson SE: Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis (1992) 19(4):185-192.
19. Mahdi OS, Byrne GI, Kalayoglu M: Emerging strategies in the diagnosis, prevention and treatment of chlamydial infections. Exp Opin Ther Pat (2001) 11(8):1253-1265.
20. Schachter J, Osoba AO: Lymphogranuloma venereum. Br Med Bull (1983) 39(2):151-154.
21. Mabey D, Peeling RW: Lymphogranuloma venereum. Sex Transm Infect (2002) 78(2):90-92.
22. CDC, sexually transmitted disease surveillance, 2000, US Department of Health and Human Services. CDC, Atlanta, GA, USA (2001).
23. Thior I, Diouf G, Diaw IK, Sarr AD, Hsieh CC, Ndoye I, Mboup S, Chen L, Essex M, Marlink R, Kanki P: Sexually transmitted diseases and risk of HIV infection in men attending a sexually transmitted diseases clinic in Dakar, Senegal. Afr J Reprod Health (1997) 1(2):26-35.
24. Wilkinson D, Rutherford G: Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev (2001) 2:CD001220.
25. Monno RC, Maggi P, Carbonara S, Sibilio G, D'Aprile A, Costa D, Pastore G: Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. AIDS Patient Care STDs (2001) 15(12):607-610.
26. Kilmarx PH, Mock PA, Levine WC: Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretions. Sex Transm Dis (2001) 28(6):347-348.
27. McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, Lavreys L, Ndinya-Achola J, Bwayo JJ, Kreiss JK: Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (2001) 15(1):105-110.
28. Chesson HW, Pinkerton SD: Sexually transmitted diseases and the increased risk for HIV transmission: Implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr (2000) 24(1):48-56.
29. Rotchford K, Strum AW, Wilkinson D: Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: Systematic review and data synthesis. Sex Transm Dis (2000) 27(5):243- 248.
30. Kuo CC, Jackson LA, Campbell LA, Grayston JT: Chlamydia pneumoniae (TWAR). Clin Microbiol Rev (1995) 8(4):451-461.
31. Gaillat J: Clinical manifestations of Chlamydia pneumoniae infections. Rev Med Interne (1996) 17(12):987-991.
32. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT: An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis (1985) 151(5):832-839.
33. Cohen CR, Brunham RC: Pathogenesis of Chlamydia induced pelvic inflammatory disease. Sex Transm Infect (1999) 75(1):21-24.
34. Schachter J: NAATs to diagnose Chlamydia trachomatis genital infection: A promise still unfulfilled. Exp Rev Mol Diagn (2001) 1(2):137-144.
35. Johnson RE, Green TA, Schachter J, Jones RB, Hook EW 3rd, Black CM, Martin DH, St Louis ME, Stamm WE: Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 38(12):4382-4386.
36. Thein J, Zhao P, Liu H, Xu J, Jha H, Miao Y, Pizzarello L, Tapert L, Schachter J, Mabon M, Osaki-Holm S et al: Does clinical diagnosis indicate ocular chlamydial infection in areas with a low prevalence of trachoma? Ophthalmic Epidemiol (2002) 9(4):263-269.
37. Stamm WE: Chlamydia trachomatis infections of the adult. In: Sexually Transmitted Diseases. Holmes KK, Lemon S, Mardh P-A, Piot P, Sparling PF, Stamm W, Wasserheit J (Eds), McGraw-Hill Professional, New York, NY, USA (1999):407-722.
38. Bragina EY, Gomberg MA, Dmitriev GA: Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol (2001) 15(5):405-409.
39. Byrne GI: Chlamydial treatment failures: A persistent problem? J Eur Acad Dermatol Venereol (2001) 15(5):381.
40. Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L: Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother (2000) 44(12):3288-3297.
41. Rees E, Tait IA, Hobson D, Karayiannis P, Lee N: Persistence of chlamydial infection after treatment for neonatal conjunctivitis. Arch Dis Child (1981) 56(3):193-198.
42. Babalola OE, Bage SD: The persistence of chlamydial inclusions in clinically quiescent trachoma. West Afr J Med (1992) 11(1):55-61.
43. Thejls H, Gnarpe J, Lundkvist O, Heimer G, Larsson G, Victor A: Diagnosis and prevalence of persistent Chlamydia infection in infertile women: Tissue culture, direct antigen detection, and serology. Fertil Steril (1991) 55(2):304-310.
44. Dean D, Suchland RJ, Stamm WE: Evidence for long-term cervical persistence of Chlamydia trachomatis by Omp1 genotyping. J Infect Dis (2000) 182(3):909-916.
45. Smith A, Munoz B, Hsieh YH, Bobo L, Mkocha H, West S: OmpA genotypic evidence for persistent ocular Chlamydia trachomatis infection in Tanzania village women. Ophthalmic Epidemiol (2001) 8(2-3):127-135.
46. Black CM, Morse SA: The use of molecular techniques for the diagnosis and epidemiologic study of sexually transmitted infections. Curr Infect Dis Rep (2000) 2(1):31-43.
47. Serlin M, Shafer MA, Tebb K, Gyamfi AA, Moncada J, Schachter J, Wibbelsman C: What sexually transmitted disease screening method does the adolescent prefer? Adolescents' attitudes toward first-void urine, self-collected vaginal swab, and pelvic examination. Arch Pediatr Adolesc (2002) 156(6):588-591.
48. Holm SO, Jha HC, Bhatta RC, Chaudhary JS, Thapa BB, Davis D, Pokhrel RP, Yinghui M, Zegans M, Schachter J, Frick KD et al: Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ (2001) 79(3):194-200.
49. Diamant J, Benis R, Schachter J, Moncada J, Pang F, Jha HC, Bhatta RC, Porco T, Lietman T: Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol (2001) 8(2-3):109-117.
50. Bain DL, Lietman T, Rasmussen S, Kalman S, Fan J, Lammel C, Zhang JZ, Dawson CR, Schachter J, Stephens RS: Chlamydial genovar distribution after community wide antibiotic treatment. J Infect Dis (2001) 184(12):1581-1588.
51. Dawson CR, Schachter J: Should trachoma be treated with antibiotics? Lancet (2002) 359(9302):184-185.
52. de la Maza MA, de la Maza LM: A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine (1995) 13(1):119-127.
53. Igietseme JU, Eko FO, Black CM: Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines (2003) 2(1):129-146.
54. Morrison RP, Caldwell HD: Immunity to murine chlamydial genital infection. Infect Immun (2002) 70(6):2741-2751.
55. Loomis WP, Starnbach MN: T cell responses to Chlamydia trachomatis. Curr Opin Microbiol (2002) 5(1):87-91.
56. Igietseme JU, Eko FO, He Q, Black CM: Antibody regulation of T-cell immunity: Implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines (2004) 3(1):23-34.
57. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H: The role of IFN-γ in the outcome of chlamydial infection. Curr Opin Immunol (2002) 14(4):444-451.
58. Fieschi C, Casanova J: The role of interleukin-12 in human infectious diseases: Only a faint signature. Eur J Immunol (2003) 33(6):1461-1464.
59. Casanova JL, Abel L: Genetic dissection of immunity to mycobacteria: The human model. Annu Rev Immunol (2002) 20:581-620.
60. Flynn JL, Chan J: Immunology of tuberculosis. Annu Rev Immunol (2001) 19:93-129.
61. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, Iademarco MF, Rothel JS: Comparison of a whole-blood interferon γ assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. J Am Med Assoc (2001) 286(14):1740-1747.
62. Brunham RC, Peeling RW: Chlamydia trachomatis antigens: Role in immunity and pathogenesis. Infect Agents Dis (1994) 3(5):218-233.
63. LaVerda D, Kalayoglu MV, Byrne GI: Chlamydial heat shock proteins and disease pathology: New paradigms for old problems? Infect Dis Obstet Gynecol (1999) 7(1-2):64-71.
64. Taylor HR, Maclean IW, Brunham RC, Pal S, Wittum-Hudson J: Chlamydial heat shock proteins and trachoma. Infect Immun (1990) 58(9):3061-3063.
65. Hassell AB, Reynolds DJ, Deacon M, Gaston JSH, Pearce JH: Identification of T-cell stimulatory antigens of Chlamydia trachomatis using synovial fluid-derived T-cell clones. Immunology (1993) 73(4):513-519.
66. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, Olinger L, Grimwood J, Davis RW, Stephens RS: Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet (1999) 21(4):385-389.
67. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, Hickey EK, Peterson J, Utterback T, Berry K, Bass S et al: Genome sequence of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res (2000) 28(6):1397-1406.
68. Stephens RS: Chlamydial genomics and vaccine antigen discovery. J Infect Dis (2000) 181(Suppl 3):S521-S523.
69. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV et al: Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science (1998) 282(5389):754-759.
70. Belland RJ, Scidmore A, Crane DD, Hogan DM, Whitmire W, McClarty G, Caldwell HD: Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc Natl Acad Sci USA (2001) 98(24):13984-13989.
71. Ward ME: Chlamydial vaccine - future trends. J Infect (1992) 1(Suppl 1):11-26.
72. Su H, Watkins NG, Zhang Y-X, Caldwell HD: Chlamydia trachomatis-host cell interactions: Role of the chlamydial major outer membrane protein as an adhesin. Infect Immun (1990) 58(4):1017-1025.
73. Wyllie S, Longbottom D, Herring AJ, Ashley RH: Single channel analysis of recombinant major outer membrane protein porins from Chlamydia psittaci and Chlamydia pneumoniae. FEBS Lett (1999) 445(1):192-196.
74. Baehr W, Zhang Y-X, Joseph T, Su H, Nano FE, Everett KD, Caldwell HD: Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Natl Acad Sci USA (1988) 85(11):4000-4004.
75. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC: Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun (2000) 68(6):3074-3078.
76. Brunham RC, Zhang DJ: Transgene as vaccine for Chlamydia. Am Heart J (1999) 138(5 Pt 2):S519-S522.
77. Stagg AJ: Vaccines against Chlamydia: Approaches and progress. Mol Med Today (1998) 4(4):166-173.
78. Jackson JW, Maisonneuve J, Taylor RB, Tian J, Yang H, Harris A: Immunization with a high molecular weight protein (pmpG) from Chlamydia trachomatis confers heterotypic protection against infertility. 101st General Meeting of the American Society for Microbiology, Orlando, FL, USA (2001):333.
79. Jen SS, Stromberg EJ, Probst P, Bhatia A, Skeiky YAW: Discovery of new vaccine candidates for prevention and treatment of Chlamydia. 101st General Meeting of the American Society for Microbiology, Orlando, FL, USA (2001):343.
80. Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, Mariani M, Manetti R, Agnusdei M, Cevenini R, Donati M et al: Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 70(1):368-379.
81. Rockey DD, Stephens RS: Genome sequencing and our understanding of chlamydiae. Infect Immun (2000) 68(10):5473-5479.
82. Stephens RS, Lammel CJ: Chlamydia outer membrane protein discovery using genomics. Curr Opin Microbiol (2001) 4(1):16-20.
83. Kawa DE, Stephens RS: Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J Immunol (2002) 168(10):5184-5191.
84. Murdin AD, Dunn P, Sodoyer R, Wang J, Caterini J, Brunham RC, Aujame L, Oomen R: Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J Infect Dis (2000) 181(Suppl 3):S544-S551.
85. Ghaem-Maghami S, Ratti G, Ghaem-Maghami M, Comanducci M, Hay PE, Bailey RL, Mabey DC, Whittle HC, Ward ME, Lewis DJ: Mucosal and systemic immune responses to plasmid protein pgp3 in patients with genital and ocular Chlamydia trachomatis infection. Clin Exp Immunol (2003) 132(3):436-442.
86. Donati M, Sambri V, Comanducci M, Di Leo K, Storni E, Giacani L, Ratti G, Cevenini R: DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. Vaccine (2003) 21(11-12):1089-1093.
87. Pal S, Theodor I, Peterson EM, de la Maza LM: Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun (2001) 69(10):6240-6247.
88. Schijns VE: Antigen delivery systems and immunostimulation. Vet Immunol Immunopathol (2002) 87(3-4):195-198.
89. Raychaudhuri S, Rock KL: Fully mobilizing host defense: Building better vaccines. Nat Biotechnol (1998) 16(11):1025-1031.
90. Green BA, Baker SM: Recent advances and novel strategies in vaccine development. Curr Opin Microbiol (2002) 5(5):483-488.
91. Fletcher MA: Vaccine candidates in STD. Int J STD AIDS (2001) 12(7):419-422.
92. Rank RG: Models of immunity. In: Chlamydia: Intracellular Biology, Pathogenesis and Immunity. Stephens RS (Ed), ASM Press, Washington, DC, USA (1999):239-295.
93. Svanholm C, Bandholtz L, Castanos-Velez E, Wigzell H, Rottenberg ME: Protective DNA immunization against Chlamydia pneumoniae. Scand J Immunol (2000) 51(4):345-353.
94. Brunham RC, Zhang DJ, Yang X, McClarty GM: The potential for vaccine development against chlamydial infection and disease. J Infect Dis (2000) 181(Suppl 3):S538-S543.
95. Zhang D, Yang X, Berry J, Shen C, McClarty G, Brunham RC: DNA vaccination with the major outer membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis (1997) 176(4):1035-1040.
96. Wizel B, Starcher BC, Samten B, Chroneos Z, Barnes PF, Dzuris J, Higashimoto Y, Appella E, Sette A: Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J Immunol (2002) 169(5):2524-2535.
97. Gurunathan S, Klinman DM, Seder RA: DNA vaccines: Immunology, application, and optimization. Annu Rev Immunol (2000) 18:927-974.
98. Vanrompay D, Cox E, Volckaert G, Goddeeris B: Turkeys are protected from infection with Chlamydia psittaci by plasmid DNA vaccination against the major outer membrane protein. Clin Exp Immunol (1999) 118(1):49-55.
99. Pal S, Barnhart KM, Wei Q, Abai AM, Peterson EM, de la Maza LM: Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine (1999) 17(5):459-465.
100. Klinman DM, Barnhart KM, Conover J: CpG motifs as immune adjuvants. Vaccine (1999) 17(1):19-25.
101. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol (1997) 158(10):4591-4601.
102. Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA: CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 161(9):4563-4571.
103. Lu H, Xing Z, Brunham RC: GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J Immunol (2002) 169(11):6324-6331.
104. Murdin AD, Su H, Klein MH, Caldwell HD: Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly cross-reactive C. trachomatis-neutralizing antibodies. Infect Immun (1995) 63(3):1116-1121.
105. Starnbach MN, Loomis WP, Ovendale P, Regan D, Hess B, Alderson MR, Fling SP: An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J Immunol (2003) 171(9):4742-4749.
106. Babiuk LA, Tikoo SK: Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J Biotechnol (2000) 83(1-2):105-113.
107. Hewson R: RNA viruses: Emerging vectors for vaccination and gene therapy. Mol Med Today (2000) 6(1):28-35.
108. Bennink JR, Yewdell JW: Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Top Microbiol Immunol (1990) 163:153-184.
109. Schlesinger S, Dubensky TW: Alphavirus vectors for gene expression and vaccine. Curr Opin Biotechnol (1999) 10(5):434-439.
110. Singh M, O'Hagan D: Advances in vaccine adjuvants. Nat Biotechnol (1999) 17(11):1075-1081.
111. Pal S, Davis HL, Peterson EM, de la Maza LM: Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun (2002) 70(9):4812-4817.
112. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM: Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine (2003) 21(13-14):1455-1465.
113. Turner MS, Giffard PM: Expression of Chlamydia psittaci- and human immunodeficiency virus-derived antigens on the cell surface of Lactobacillus fermentum BR11 as fusion to bspA. Infect Immun (1999) 67(10):5486-5489.
114. Gentschev I, Dietrich G, Spreng S, Kolb-Maurer A, Daniels J, Hess J, Kaufmann SH, Goebel W: Delivery of protein antigens and DNA by virulence-attenuated strains of Salmonella typhimurium and Listeria monocytogenes. J Biotechnol (2000) 83(1-2):19- 26.
115. Eko FO, Witte A, Huter V, Kuen B, Furst-Ladani S, Haslberger A, Katinger A, Hensel A, Szostak MP, Resch S, Mader H et al: New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine (1999) 17(13-14):1643-1649.
116. Igietseme JU, Black CM, Caldwell HD: Chlamydia vaccine: Strategies and status. BioDrugs (2002) 16(1):19-35.
117. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, Lyn D, Black CM, Igietseme JU: Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine (2003) 21(15):1694-1703.
118. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD: Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med (1998) 188(5):809-818.
119. Igietseme JU, Ananaba GA, Bolier J, Bowers S, Moore T, Belay T, Eko FO, Lyn D, Black CM: Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for enhanced specific Th1 induction: Potential for cellular vaccine development. J Immunol (2000) 164(8):4212-4219.
120. Citterio S, Rescigno M, Foti M, Granucci F, Aggujaro D, Gasperi C, Matyszak MK, Girolomoni G, Ricciardi-Castagnoli P: Dendritic cells as natural adjuvants. Methods (1999) 19(1):142-147.
121. Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, Hofhuis FM, Guyre PM, Capel PJ, Verbeek JS, van de Winkel JG: Antigen targeting to myeloid-specific human Fc RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest (1996) 97(2):331-338.
122. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM: Enhanced antigen presentation using human Fc receptor (monocyte/macrophage)- specific immunogens. J Immunol (1992) 149(11):3477-3481.
123. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO, Igietseme JU: Fc receptors regulation of protective immunity against Chlamydia trachomatis. Immunology (2002) 105(2):213-221.
124. Moore T, Ekworomadu C, Eko F, MacMillan L, Ramey K, Ananaba GA, Patrickson JW, Nagappan PR, Lyn D, Black CM, Igietseme JU: Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis (2003) 188(4):617-624.
125. Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDonald AB: Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat Med (1996) 2(10) 1116-1121.
126. Whittum-Hudson JA, Rudy D, Gerard H, Vora G, Davis E, Haller PK, Prattis SM, Hudson AP, Saltzman WM, Stuart ES: The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis. Vaccine (2001) 19(28-29):4061-4071.
127. Wu H-Y, Russell MW: Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res (1997) 16(2):187-201.
128. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM: Mucosal immunity: Implications for vaccine development. Immunobiology (1992) 184(2-3):157-179.
129. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H: The mucosal immune system: From fundamental concepts to vaccine development. Vaccine (1992) 10(2):75-88.
130. Pal S, Peterson EM, de la Maza LM: Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun (1996) 64(12):5341-5348.
131. Pal S, Theodor I, Peterson EM, de la Maza LM: Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun (1997) 65(8):3361-3369.
132. Igietseme JU, Uriri IM, Kumar SN, Ananaba GA, Ojior OO, Momodu IA, Candal DH, Black CM: Route of infection that induces a high intensity of γ interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 66(9):4030-4035.
133. Wu HY, Nikolova EB, Beagley KW, Russell MW: Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue. Immunology (1996) 88(4):493-500.
134. Gallichan WS, Rosenthal KL: Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine (1995) 13(16):1589-1595.
135. Staats HF, Montgomery SP, Palker TJ: Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses (1997) 13(11):945-952.
136. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 187(1):129-134.
137. Igietseme JU, Rank RG: Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Infect Immun (1991) 59(4):1346- 1351.
138. Kelly KA, Rank RG: Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun (1997) 65(12):5198-5208.
139. Igietseme JU, Portis JL, Perry LL: Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae. Infect Immun (2001) 69(3):1832-1840.
140. Igietseme JU, Murdin A: Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun (2000) 68(12):6798-6806.
141. FluMist. The Investigational Drugs Database (IDdb) (2004). www.iddb3.com.
142. Gruber WC: The role of live influenza vaccines in children. Vaccine (2002) 20(Suppl 2):S66-S73.
143. Watanabe T, Watanabe S, Noda T, Fujii Y, Kawaoka Y: Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes. J Virol (2003) 77(19):10575-10583.
144. Gilboa E, Nair SK, Lyerly HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother (1998) 46(2):82-87.
145. Hajek R, Butch AW: Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol (2000) 17(1):2-15.
146. Reid CD: The biology and clinical applications of dendritic cells. Transfus Med (1998) 8(2):77-86.